Aaron Pierce, MD
Sleep Medicine · Dallas, TXNPI 1477842896
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,119 of the $6,358 with a category attached, or 80.5%. 30 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 26.8% of the total.
Across 243 payments — averaging $26.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$2K
- Jazz Pharmaceuticals Inc.$914
- Harmony Biosciences LLC$664
- Axsome Therapeutics, Inc.$539
- Avadel CNS Pharmaceuticals, LLC$310
- ZOLL Respicardia, Inc.$293
- plus $2K from 24 others
What the payments were for
- Consulting fees$3506%
- Travel & lodging$5058%
- Food & beverage$5,11981%
- Education$3846%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 29 | $1,701 |
| Jazz Pharmaceuticals Inc. | 36 | $914 |
| Harmony Biosciences LLC | 42 | $664 |
| Axsome Therapeutics, Inc. | 25 | $539 |
| Avadel CNS Pharmaceuticals, LLC | 7 | $310 |
| ZOLL Respicardia, Inc. | 5 | $293 |
| Mylan Specialty L.p. | 15 | $280 |
| Merck | 12 | $241 |
| Boehringer Ingelheim | 13 | $191 |
| Idorsia Pharmaceuticals US Inc | 7 | $164 |
| Regeneron Healthcare Solutions, Inc. | 6 | $139 |
| AstraZeneca | 6 | $91 |
| Actelion Pharmaceuticals US, Inc. | 3 | $84 |
| Mayne Pharma Commercial LLC | 4 | $84 |
| UCB, Inc. | 2 | $75 |
| Novartis | 4 | $68 |
| Itamar Medical Inc | 1 | $64 |
| Electromed, Inc. | 4 | $64 |
| Shire North American Group Inc | 3 | $56 |
| Philips North America LLC | 3 | $54 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| Fisher & Paykel Healthcare Inc | 2 | $43 |
| Arbor Pharmaceuticals, Inc. | 3 | $35 |
| 3b Medical, Inc. | 2 | $32 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Vapotherm Inc | 1 | $25 |
| Circassia Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $13 |
| Insmed, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$737
- Inspire Upper Airway Stimulation System$452
- LUMRYZ$200
- XYWAV$150
- XYREM$150
- remede System$139
- SUNOSI$118
How this compares
$6,358 in reported general payments places this provider in the 80th percentile of 112 sleep medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelsomraSuvorexant | 46 | $32,154 |
| SunosiSolriamfetol Hcl | 14 | $24,493 |
| DayvigoLemborexant | 16 | $7,619 |
| Doxepin Hcl | 211 | $4,417 |
| Modafinil | 30 | $3,861 |
| Zolpidem Tartrate | 81 | $2,085 |
| Ropinirole Hcl | 92 | $2,066 |
| Ropinirole ErRopinirole Hcl | 12 | $1,516 |
| Temazepam | 48 | $1,506 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 45 | $1,260 |
| Gabapentin | 117 | $1,208 |
| Armodafinil | 17 | $837 |
| Methylphenidate Hcl | 14 | $795 |
| Eszopiclone | 37 | $731 |
| Trazodone Hcl | 54 | $514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckBelsomra | $241 | $32,15446 claims |
| Axsome Therapeutics, Inc.Sunosi | $539 | $24,49314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 112 sleep medicine providers in Texas.
Other sleep medicine in Dallas
- John DebusDallas$38K
- Nabeel FarahDallas$6K
- Andrew JamiesonDallas$5K
- Jack GardnerDallas$5K
- Tuyet PhamDallas$4K
- Sejal JainDallas$2K
- Rupini AllaDallas$2K
- Katie TranDallas$2K
- Arunkumar BadiDallas$1K
- Gerard MeskillSugar Land$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.